This is a comprehensive, 100-hour continuing education program designed to strengthen physician associates'/assistants' knowledge and clinical decision-making across a broad range of common and complex conditions affecting adult health. The curriculum integrates evidence-based approaches to cardiovascular and metabolic disease, musculoskeletal and neurologic disorders, behavioral health, pain and substance-related concerns, and ethical and end-of-life care. Topics include heart failure, hypertension, diabetes, overweight and obesity, osteoporosis, back pain, Parkinson disease, behavioral addictions, opioid safety, anabolic steroid use, medical ethics, and counseling patients and families at the end of life. The program also addresses the evidence, safety considerations, and potential drug interactions associated with natural medicines and dietary supplements used for depression, anxiety, and weight loss. Emphasizing whole-person care, this program equips physician assistants to apply current evidence and clinical principles to the assessment, management, counseling, and ongoing care of diverse adult patients.
- 1. Part I— Treatment of Heart Failure: An Update — 10 CREDITS
- 2. Part II — Hypertension: Strategies to Improve Outcomes — 5 CREDITS
- 3. Part III — Low Back Pain — 15 CREDITS
- 4. Part IV — Alternative Therapies for Depression and Anxiety — 5 CREDITS
- 5. Part V — Medical and Illicit Use of Anabolic Steroids — 5 CREDITS
- 6. Part VI — Supplements for Weight Loss — 5 CREDITS
- 7. Part VII — Type 2 Diabetes: Treatment Strategies for Optimal Care — 5 CREDITS
- 8. Part VIII — Diagnosing and Treating Overweight and Obese Patients — 5 CREDITS
- 9. Part IX — Osteoporosis: Diagnosis and Management — 5 CREDITS
- 10. Part X — Behavioral Addictions — 15 CREDITS
- 11. Part XI — Parkinson Disease — 10 CREDITS
- 12. Part XII — Counseling Patients at the End of Life — 5 CREDITS
- 13. Part XIII — Medical Ethics for Physicians — 5 CREDITS
- 14. Part XIV — Opioid Safety: Balancing Benefits and Risks — 5 CREDITS
This course is designed for physician assistants and interested healthcare professionals.
Patricia Lea, RN, DNP, MSEd, CCRN, received a Bachelor of Science degree in Nursing in 1973 from Houston Baptist University in Houston, Texas. She returned to graduate school to complete a Master’s degree in Education, specifically Health Education, in 1996 from Baylor University in Waco, Texas, and a Doctorate in Nursing Practice in Executive Leadership in 2014 from American Sentinel University in Aurora, Colorado. Dr. Lea specializes in critical care nursing, with an emphasis on heart failure and sepsis. She started her career at the Houston Methodist Hospital in the cardiovascular ICU and opened an acute dialysis unit at what is now Baylor St. Luke’s Medical Center in the Houston Medical Center. Dr. Lea was a Cardiovascular Clinical Coordinator and Director of the Heart Failure Clinic at Hillcrest Baptist Medical Center in Waco, Texas. In 2004, Dr. Lea returned to Houston and was employed as a Senior Research Clinical Nurse Specialist at the Texas Heart Institute coordinating stem cell and cardiac stent trials. She is currently Associate Professor and Baccalaureate Program Director at the University of Texas Medical Branch School of Nursing in Galveston, Texas.
John J. Whyte, MD, MPH, is currently the Chief Medical Officer at WebMD. In this role, he leads efforts to develop and expand strategic partnerships that create meaningful change around important and timely public health issues. Previously, Dr. Whyte was the Director of Professional Affairs and Stakeholder Engagement at the FDA’s Center for Drug Evaluation and Research and the Chief Medical Expert and Vice President, Health and Medical Education at Discovery Channel, part of the media conglomerate Discovery Communications.
Prior to this, Dr. Whyte was in the Immediate Office of the Director at the Agency for Healthcare Research Quality. He served as Medical Advisor/Director of the Council on Private Sector Initiatives to Improve the Safety, Security, and Quality of Healthcare. Prior to this assignment, Dr. Whyte was the Acting Director, Division of Medical Items and Devices in the Coverage and Analysis Group in the Centers for Medicare & Medicaid Services (CMS). CMS is the federal agency responsible for administering the Medicare and Medicaid programs. In his role at CMS, Dr.Whyte made recommendations as to whether or not the Medicare program should pay for certain procedures, equipment, or services. His division was responsible for durable medical equipment, orthotics/prosthetics, drugs/biologics/therapeutics, medical items, laboratory tests, and non-implantable devices. As Division Director as well as Medical Officer/Senior Advisor, Dr. Whyte was responsible for more national coverage decisions than any other CMS staff.
Dr. Whyte is a board-certified internist. He completed an internal medicine residency at Duke University Medical Center as well as earned a Master’s of Public Health (MPH) in Health Policy and Management at Harvard University School of Public Health. Prior to arriving in Washington, Dr. Whyte was a health services research fellow at Stanford and attending physician in the Department of Medicine. He has written extensively in the medical and lay press on health policy issues.
Mark Rose, BS, MA, LP, is a licensed psychologist in the State of Minnesota with a private consulting practice and a medical research analyst with a biomedical communications firm. Earlier healthcare technology assessment work led to medical device and pharmaceutical sector experience in new product development involving cancer ablative devices and pain therapeutics. Along with substantial experience in addiction research, Mr. Rose has contributed to the authorship of numerous papers on CNS, oncology, and other medical disorders. He is the lead author of papers published in peer-reviewed addiction, psychiatry, and pain medicine journals and has written books on prescription opioids and alcoholism published by the Hazelden Foundation. He also serves as an Expert Advisor and Expert Witness to law firms that represent disability claimants or criminal defendants on cases related to chronic pain, psychiatric/substance use disorders, and acute pharmacologic/toxicologic effects. Mr. Rose is on the Board of Directors of the Minneapolis-based International Institute of Anti-Aging Medicine and is a member of several professional organizations.
Chelsey McIntyre, PharmD, is a clinical pharmacist who specializes in drug information, literature analysis, and medical writing. She earned her Bachelor of Science degree in Genetics from the University of California, Davis. She then went on to complete her PharmD at Creighton University, followed by a clinical residency at the Children’s Hospital of Philadelphia (CHOP). Dr. McIntyre held the position of Drug Information and Policy Development Pharmacist at CHOP until her move to Washington state in 2017, after which she spent the next six years as a clinical editor for Natural Medicines, a clinical reference database focused on natural products and alternative therapies. She continues to create rigorous professional analysis and patient education materials for various publications while also practicing as a hospital pharmacist. Her professional interests include provider and patient education, as well as the application of evidence-based research to patient care.
Lisa Hutchison, LMHC, has more than 20 years of experience providing individual and group counseling with adults. She specifically focuses on teaching assertiveness, stress management, and boundary setting for empathic helpers. Ms. Hutchison graduated from the University of Massachusetts, Boston, with a Master’s degree in education for mental health counseling.
John M. Leonard, MD, Professor of Medicine Emeritus, Vanderbilt University School of Medicine, completed his post-graduate clinical training at the Yale and Vanderbilt University Medical Centers before joining the Vanderbilt faculty in 1974. He is a clinician-educator and for many years served as director of residency training and student educational programs for the Vanderbilt University Department of Medicine. Over a career span of 40 years, Dr. Leonard conducted an active practice of general internal medicine and an inpatient consulting practice of infectious diseases.
Contributing faculty, Patricia Lea, RN, DNP, MSEd, CCRN, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, John J. Whyte, MD, MPH, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, Mark Rose, BS, MA, LP, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, Chelsey McIntyre, PharmD, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, Lisa Hutchison, LMHC, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Contributing faculty, John M. Leonard, MD, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
John V. Jurica, MD, MPH
John M. Leonard, MD
The division planners have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.
Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.
Supported browsers for Windows include Microsoft Internet Explorer 9.0 and up, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and CSS 2.0 may work, but are not supported. Supported browsers must utilize the TLS encryption protocol v1.1 or v1.2 in order to connect to pages that require a secured HTTPS connection. TLS v1.0 is not supported.
#41970: The Adult Patient: Evidence-Based Care for Mind and Body
Part 11 of 14 · Chapter 1 of 10
Table of Contents
The purpose of this course is to provide physicians, nurses, and other members of the interprofessional healthcare team a review of pathogenesis, disease progression, diagnosis, and management of Parkinson disease, in order to improve patient care and quality of life.
Upon completion of this course, you should be able to:
- Outline the history of Parkinson disease (PD) and scientific developments related to recognition of the disease.
- Integrate epidemiologic considerations, risk factor assessment, and defining clinical features into a framework for evaluating a patient with suspected Parkinson disease.
- Assess motor and non-motor symptoms and signs in relation to pathophysiology of PD.
- Anticipate the time course of symptom development in patients with PD, and use this to assess clinical probability and to inform follow-up of a patient in whom the diagnosis is unclear.
- Refine history and clinical examination skills in order to detect the early motor and non-motor signs and symptoms of PD.
- Develop a strategy for the initial workup of patients with suspected PD that conforms with diagnostic and clinical staging criteria.
- Compare and contrast syndromes that may mimic PD and their differential diagnosis.
- Devise a treatment strategy and select an appropriate drug regimen for the management of PD.
- Create an approach to the management of PD based on stage of the disease, severity of symptoms, and rate of progression.
- Discuss the role of non-motor symptoms of PD and devise a strategy for treatment.
- Outline a long-term plan for monitoring the course of PD illness, including patient and family education and safety precautions.
Parkinson disease (PD) is a chronic, slowly progressive neurodegenerative disease affecting approximately 1% of adults older than 60 years of age [1,2]. Advances in the understanding of PD pathophysiology have improved recognition of both non-motor and motor symptoms that characterize each stage of disease progression, which in turn facilitates early diagnosis and therapeutic intervention. Timely diagnosis and the application of therapeutic options tailored to the disease stage promotes a better quality life for patients with PD [3,4]. As a chronic illness, patients with PD benefit from regular follow-up with their primary care provider working in concert with a neurology consultant and an interprofessional care team. Important aspects of care include need to adjust dosage or alter drug treatment, attention to medication side effects/toxicity, management of comorbid conditions, and risk of polypharmacy. This course will review pathophysiology, clinical features, principles of diagnosis and treatment in relation to stage of PD, and other considerations important to optimal patient care.
1. DeMaagd G, Philip A. Parkinson's disease and its management. Part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. PT. 2015;40(8):504-532.
2. Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Physician. 2013;87(4):267-273.
3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26(Suppl 1):S1-S58.
6. National Institute of Neurological Disorders and Stroke. Parkinson's Disease: Challenges, Progress, and Promise. Available at https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise. Last accessed April 21, 2025.
7. Scottish Intercollegiate Guidelines Network. Diagnosis and Pharmacological Management of Parkinson's Disease: A National Clinical Guideline. Available at https://www.parkinsons.org.uk/sites/default/files/2018-10/SIGN%20guideline%20Diagnosis%20and%20pharmacological%20management%20of%20Parkinson%27s.pdf. Last accessed April 21, 2025.
8. Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson's disease. Subcell Biochem. 2012;65:389-455.
9. Parkinson's Foundation, Statistics. Available at https://www.parkinson.org/Understanding-Parkinsons/Statistics. Last accessed April 21, 2025.
10. Van Den Eeden SK. Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.Am J Epidemiol. 2003;157(11):1015-1022.
11. Murphy SL, Kochanek KD, Xu JQ, Arias E. Deaths: final data for 2021. Natl Vital Stat Rep. 2024;73(8):1-139.
12. Barreto GE, Iakov A, Moran VE. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neurosci. 2015;6:340.
13. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol. 2009;78(7):677-685.
14. Kenborg L, Lassen CF, Ritz B, et al. Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study. Am J Epidemiol. 2015;181(10):808-816.
15. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 2012;175(11):1200-1207.
16. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010;74(11):878-884.
17. Liu R, Guo X, Park Y, et al. Alcohol consumption, types of alcohol, and Parkinson's disease. PLoS One. 2013;8(6):e66452.
18. Jung SY, Chun S, Cho EB, et al. Changes in smoking, alcohol consumption, and the risk of Parkinson's disease. Front Aging Neurosci. 2023;15:1223310.
19. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010;183:183-208.
20. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35(7):949-956.
21. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA. Designer drugs: a medicinal chemistry perspective. Ann NY Acad Sci. 2012;1248:18-38.
22. Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 1994;36(5):765-770.
24. Stern Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology. 1990;40(2):261-264.
25. Fernagut PO, Hutson CB, Fleming SM, et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse. 2007;61(12):991-1001.
26. Feng LR, Maguire-Zeiss KA. Dopamine and paraquat enhance alpha-synuclein-induced alterations in membrane conductance. Neurotox Res. 2011;20(4):387-401.
27. Lu L, Gu L, Liang Y, Sun X, Duan C, Yang H. Dual effects of alpha-synuclein on neurotoxicity induced by low dosage of rotenone are dependent on exposure time in dopaminergic neuroblastoma cells. Sci China Life Sci. 2010;53(5):590-597.
28. Ma KL, Yuan YH, Song LK, et al. Over-expression of alpha-synuclein 98 triggers intracellular oxidative stress and enhances susceptibility to rotenone. Neurosci Lett. 2011;491(2):148-152.
29. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015;146:30-38.
30. Vieira-Brock PL, McFadden LM, Nielsen SM, et al. Chronic nicotine exposure attenuates methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther. 2015;355(3):463-472.
31. Wang YL, Wang YT, Li JF, Zhang YZ, Yin HL, Han B. Body mass index and risk of Parkinson's disease: a dose-response meta-analysis of prospective studies. PLoS One. 2015;10(6):e0131778.
32. Tanner CM, Goldman SM, Ross GW, Grate SJ. The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. Alzheimers Dement. 2014;10(3 Suppl):S213-S225.
33. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281(4):341-346.
34. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651-1661.
35. Gao J, Nalls MA, Shi M, et al. An exploratory analysis on gene-environment interactions for Parkinson disease. Neurobiol Aging. 2012;33(10):1-6.
36. Ong YL, Deng X, Li HH, et al. Caffeine intake interacts with Asian gene variants in Parkinson's disease: a study in 4488 subjects. Lancet Reg Health West Pac. 2023;40:100877.
37. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins.Ann Neurol. 2006;60(1):65-72.
38. Goldman SM, Kamel F, Ross GW, et al. Head injury, alpha-synuclein Rep1 and Parkinson's disease. Ann Neurol. 2012;71(1):40-48.
39. Perez XA. Preclinical evidence for a role of the nicotinic cholinergic system in Parkinson's disease. Neuropsychol Rev. 2015;25(4):371-383.
40. Camilleri A, Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease. CNS Neurosci Ther. 2014;20(7):591-602.
41. Celardo I, Martins LM, Gandhi S. Unravelling mitochondrial pathways to Parkinson's disease. Br J Pharmacol. 2014;171(8):1943-1957.
42. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132-144.
43. Del Tredici K, Braak H. Sporadic Parkinson's disease: development and distribution of α-synuclein pathology. Neuropatholo Appl Neurobiol. 2015;42(1):33-50.
44. Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70(20):1916-1925.
45. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8(12):1150-1157.
46. Ray B, Mahalakshmi AM, Tuladhar S, et al. "Janus-Faced" α-Synuclein: Role in Parkinson's Disease. Front Cell Dev Biol. 2021;9:673395.
47. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121-134.
48. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010;16(2):79-84.
49. Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81(18):1611-1616.
50. Chahine LM, Merchant K, Siderowf A, et al. Proposal for a Biologic Staging System of Parkinson's Disease. J Parkinsons Dis. 2023;13(3):297-309.
51. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024/23(2):178-190.
52. Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014;184(4):966-975.
53. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol. 2008;34(3):284-295.
54. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2015;14(1):57-64.
55. Braak H, Bohl JR, Muller CM, et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006;21(12):2042-2051.
56. Williams DR, Lees AJ. How do patients with parkinsonism present? A clinicopathological study. Intern Med J. 2009;39(1):7-12.
57. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
58. Postuma RB, Gagnon JF, Bertrand JA, Genier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104-1113.
59. Postuma RB, Gagnon JF, Montplaisir JY. REM sleep behavior disorder and prodromal neurodegeneration: where are we headed? Tremor Other Hyperkinet Mov (N Y). 2013;3.
60. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744-748.
61. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59(4):591-596.
62. Abbott RD, Ross GW, White LR, et al. Environmental, lifestyle, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol. 2003;250(Suppl 3):III3-III39.
63. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442-1446.
64. Soto-Ortolaza AI, Ross OA. Genetic susceptibility variants in parkinsonism. Parkinsonism Relat Disord. 2016;22(Suppl 1):S7-S11.
65. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1599.
66. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015;30(12):1600-1611.
67. Massano J, Bhatia KP. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012;2(6):a008870.
68. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013;20(1):16-34.
69. international Parkinson and Movement Disorder Society. Parkinson's Disease and Parkinsonism. Available at https://www.movementdisorders.org/MDS/About/Movement-Disorder-Overviews/Parkinsons-Disease--Parkinsonism.htm. Last accessed April 21, 2025.
70. Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson's disease. Nat Rev Neurol. 2015;11(2):98-110.
71. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
72. Spildooren J, Vercruysse S, Desloovere K, Vandenberghe W, Kerckhofs E, Nieuwboer A. Freezing of gait in Parkinson's disease: the impact of dual-tasking and turning. Mov Disord. 2010;25(15):2563-2570.
73. Plotnik M, Giladi N, Dagan Y, Hausdorff JM. Postural instability and fall risk in Parkinson's disease: impaired dual tasking, pacing, and bilateral coordination of gait during the "ON" medication state. Exp Brain Res. 2011;210(3-4):529-538.
74. Todorova A, Jenner P, Chaudhuri KR. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol. 2014;14(5):310-322.
75. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
76. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170.
77. Bondon-Guiton E, Perez-Loret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226-2231.
78. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975.
79. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013;20(1):5-15.
80. Domingo-Echaburu S, Lertxundi U, Gonzalo-Olazabal E, et al. Inappropriate antidopaminergic drug use in Parkinson's disease inpatients. Curr Drug Ther. 2012;7(3):164-169.
81. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996-1002.
82. Bergquist F, Horne M. Can objective measurements improve treatment outcomes in Parkinson's disease? Eur Neurol Rev. 2014;9(1):27-30.
83. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the united Parkinson's disease rating scale. Arch Neurol. 2010;67(1):64-70.
84. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5).
85. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010;25(2):149-156.
86. Jenner P. Treatment of the later stages of Parkinson's disease: pharmacological approaches now and in the future. Transl Neurodegener. 2015;4:3.
87. Bressman S, Saunders-Pullman R. When to start levodopa therapy for Parkinson's disease. N Engl J Med. 2019;380:389-390.
88. Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord. 2013;28(8):1064-1071.
89. Kuhl MM. Get with the Times: Parkinson's Diagnosis Criteria Catches Up with Latest Understanding. Available at https://www.michaeljfox.org/news/get-times-parkinsons-diagnosis-criteria-catches-latest-understanding?get-with-the-times-parkinson-diagnosis-criteria-catches-up-with-latest-understanding. Last accessed April 21, 2025.
90. Malek N, Grosset DG. Medication adherence in patients with Parkinson's disease. CNS Drugs. 2015;29(1):47-53.
91. Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurol. 2007;7:20.
92. Fleisher JE, Stern MB. Medication nonadherence in Parkinson's disease. Curr Neurol Neurosci Rep. 2013;13(10):382.
93. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-e33.
94. DeMaagd G, Philip A. Parkinson's disease and its management. Part 2: introduction to the pharmacotherapy of Parkinson's disease, with a focus on the use of dopaminergic agents. PT. 2015;40(9):590-600.
95. Grimes D, Gordon J, Snelgrove B, et al. Canadian guidelines on Parkinson's disease. Can J Neurol Sci. 2012;39(Suppl 4):S1-S30.
96. LexiDrug. Available at https://online.lexi.com. Last accessed April 21, 2025.
97. Ahiskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Discord. 2001;16:448-458.
98. U.S. Food and Drug Administration. Pergolide (marketed as Permax) Information. Available at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pergolide-marketed-permax-information. Last accessed April 21, 2025.
99. Fox SH, Katzenschlager R, Lim S-Y, et al. Update on Treatments for Motor Symptom of PD. Available at https://www.movementdisorders.org/MDS-Files1/PDFs/EBM-Papers/UPDATEFORWEBSITEMOTORTREATMENTFORPD_TEXT_9FEB2015_FINALTEXT.pdf. Last accessed April 21, 2025.
100. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-1053.
101. Stathis P, Konitsiotis S, Antonina A. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Rev Neurother. 2015;15(2):207-213.
102. Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson's disease. Expert Opin Investig Drugs. 2014;23(3):387-410.
103. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278.
104. DeMaagd G, Philip A. Parkinson's disease and its management. Part 3: nondopaminergic and nonpharmacological treatment options. PT. 2015;40(10):668-679.
105. Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154-165.
106. Giugni JC, Okun MS. Treatment of advanced Parkinson's disease. Curr Opin Neurol. 2014;27(4):450-460.
107. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord. 2006;21(4):456–61.
108. Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37(1):9-16.
109. U.S. Food and Drug Administration. FDA Approves New Add-On Drug to Treat Off Episodes in Adults with Parkinson's Disease. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-disease. Last accessed April 21, 2025.
110. Shook BC, Jackson PF. Adenosine A2A receptor antagonists and Parkinson's disease. ACS Chem Neurosci. 2011;2(10):555-567.
111. Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord. 2013;28(8):1138-1141.
112. Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord. 2014;29:1273-1280.
113. Zuardi A W, Crippa J, Hallak J, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009;23(8):979-983.
114. Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564-566.
115. Pasternak B, Svanström H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol. 2012;175(7):627-635.
116. Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11(7):589-596.
117. Simuni T, Brundin P. Is exenatide the next big thing in Parkinson's disease? J Parkinsons Dis. 2014;4(3):345-347.
118. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013;123(6):2730-2736.
119. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68(1):45-50.
120. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683.
121. Korczyn AD, Hassin-Baer S. Can the disease course in Parkinson's disease be slowed? BMC Medicine. 2015;13:295.
122. American Academy of Neurology. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease. Available at https://www.aan.com/Guidelines/home/GuidelineDetail/1043. Last accessed April 21, 2025.
123. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol. 2010;63(5):257-266.
124. Müller T. Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert Opin Drug Metab Toxicol. 2011;7(7):847-855.
125. Gershanik OS. Clinical problems in late-stage Parkinson's disease. J Neurol. 2010;257(Suppl 2):S288-S291.
126. Teichholtz H. FDA Approves Duopa, Carbidopa/Levodopa Enteral Suspension Method New to U.S. Market. Available at https://www.michaeljfox.org/foundation/news-detail.php?fda-approves-duopa-levodopa-carbidopa-intestinal-gel-delivery-method-new-to-market. Last accessed April 21, 2025.
127. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141-149.
129. Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010;25(5):578-586.
130. Le Goff F, Derrey S, Lefaucheur R, et al. Decline in verbal fluency after subthalamic nucleus brain stimulation in Parkinson's disease: a microlesion effect of the electrode trajectory. J Parkinsons Dis. 2015;5(1):95-104.
131. Fasano A, Lozano AM. Deep brain stimulation for movement disorders: 2015 and beyond. Curr Opin Neurol. 2015;28(4):423-436.
132. Medtronic. Medtronic Earns U.S. DA Approval for the World's First Adaptive Deep Brain Stimulation System for People With Parkinson's. Available at https://news.medtronic.com/2025-02-24-Medtronic-earns-U-S-FDA-approval-for-the-worlds-first-Adaptive-deep-brain-stimulation-system-for-people-with-Parkinsons. Last accessed April 21, 2025.
133. National Institutes of Health. Personalized Deep Brain Stimulation for Parkinson's Disease. Available at https://www.nih.gov/news-events/nih-research-matters/personalized-deep-brain-stimulation-parkinson-s-disease. Last accessed April 21, 2025.
134. Pozzi NG, Isaias IU. Adaptive deep brain stimulation: Retuning Parkinson's disease. Handb Clin Neurol. 2022;184:273-284.
135. Fénelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-766.
136. Bhatti D, Torres-Russotto DR. Pharmacological management of psychosis in Parkinson disease: a review. Curr Drug Ther. 2012;7(3):151-163.
137. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology. 2010;75(14):1270-1276.
138. de Maindreville AD, Fénelon G, Mahieux F. Hallucinations in Parkinson's disease: a follow-up study. Mov Disord. 2005;20(2):212-217.
139. Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol. 2006;63(9):1343-1344.
140. Zesiewicz TA, Sullivan KI, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease. Neurology. 2010;74(11):924-931.
141. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165-171.
142. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340(10):757-763.
143. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353(9169):2041-2042.
144. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005;20(8):958-963.
145. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007;22(3):313-318.
146. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540.
147. DeMaagd G, Philip A. Parkinson's disease and its management. Part 5: treatment of nonmotor complications. PT. 2015;40(12): 838-846.
148. Alnajjar AZ, Abouelmagd ME, Krayim A, AbdelMeseh M, Bushara N, Nabil Y. Efficacy of cognitive behavioral therapy for anxiety and depression in Parkinson's disease patients: an updated systematic review and meta-analysis. Neurol Sci. 2024;45(11):5277-5290.
149. Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS One. 2013;8(11):e79510.
150. Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis. 2015;2015:609428.
151. Takamiya A, Seki M, Kudo S, et al. Electroconvulsive therapy for Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2021;36(1):50-58.
152. Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH. Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord. 2016;23:62-65.
153. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668-674.
154. Mai AS, Lee YS, Yong JH, Teo DCYJ, Wan YM, Tan EK. Treatment of apathy in Parkinson's disease: A bayesian network meta-analysis of randomised controlled trials. Heliyon. 2024;10(4):e26107.
155. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009;32(6):475-88.
156. Santiago P-L, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261-265.
157. Nomura T, Inoue Y, Miyake M, Yasui K, Nakashima K. Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord. 2006;21(3):380-384.
158. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008;23(16):2267-2302.
159. Antonini A, Tinazzi M. Targeting pain in Parkinson's disease. Lancet Neurol. 2015;14(12):1144-1145.
160. Tinazzi M, Del Vesco C, Defazio G, et al. Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 laser evoked potentials. Pain. 2008;136(1-2):117-124.
161. Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. J Neurol. 2015;262(9):2164-2170.
162. van Rooden SM, Verbaan D, Stijnen T, van Hilten JJ. The influence of age and approaching death on the course of nondopaminergic symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2016;24:113-118.
163. Lokk J, Delbari A. Clinical aspects of palliative care in advanced Parkinson's disease. BMC Palliat Care. 2012;11:20.
164. National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence; 2006.
165. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med. 2012;366:511-519.
166. American Parkinson Disease Association. Parkinson's Training for Fitness, Health and Wellness Professionals. Available at https://www.apdaparkinson.org/pd-fitness-training. Last accessed April 21, 2025.
167. U.S. Census Bureau. Selected Social Characteristics in the United States: 2023 American Community Survey 5-Year Estimates. Available at https://data.census.gov/table/ACSDP5Y2023.DP02. Last accessed April 21, 2025.
168. Karliner LS, Napoles-Springer AM, Schillinger D, Bibbins-Domingo K, Pérez-Stable EJ. Identification of limited English proficient patients in clinical care. J Gen Intern Med. 2008;23(10):1555-1560.
169. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3):255-299.
170. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.
171. Flores G. Language barriers to health care in the United States. N Engl J Med. 2006;355(3):229-231.
172. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care. J Gen Intern Med. 2003;18(1):44-52.
173. Van Dongen JJJ, van Bokhoven MA, Daniels R, et al. Developing interprofessional care plans in chronic care: a scoping review. BMC Family Practice. 2016;17:1-9.
174. Donovan AL, Aldrich JM, Gross AK, et al. Interprofessional care and teamwork in the ICU. Crit Care Med. 2018;46:980-990.
Part 11 of 14 · Chapter 1 of 10
Mention of commercial products does not indicate endorsement.